Cargando…

Identification of immune‐enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma

Ovarian carcinoma has the highest mortality among the malignant tumours in gynaecology, and new treatment strategies are urgently needed to improve the clinical status of ovarian carcinoma patients. The Cancer Genome Atlas (TCGA) cohort were performed to explore the immune function of the internal e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Mingjun, Hu, Yuexin, Gou, Rui, Liu, Ouxuan, Nie, Xin, Li, Xiao, Liu, Qing, Hao, Yingying, Liu, Juanjuan, Lin, Bei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077593/ https://www.ncbi.nlm.nih.gov/pubmed/31995855 http://dx.doi.org/10.1111/jcmm.14830

Ejemplares similares

Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer
por: Gou, Rui, et al.
Publicado: (2022)

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair
por: Gou, Rui, et al.
Publicado: (2022)

Identification of the prognostic value of a 2-gene signature of the WNT gene family in UCEC using bioinformatics and real-world data
por: Hu, Yuexin, et al.
Publicado: (2021)

YWHAE as an HE4 interacting protein can influence the malignant behaviour of ovarian cancer by regulating the PI3K/AKT and MAPK pathways
por: Li, Xiao, et al.
Publicado: (2021)

Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma
por: Zheng, Mingjun, et al.
Publicado: (2019)

Oxidative Stress Response Biomarkers of Ovarian Cancer Based on Single-Cell and Bulk RNA Sequencing
por: Zheng, Mingjun, et al.
Publicado: (2023)

PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes
por: Gou, Rui, et al.
Publicado: (2021)

ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15
por: Wang, Shuang, et al.
Publicado: (2020)

Keratin 80 regulated by miR-206/ETS1 promotes tumor progression via the MEK/ERK pathway in ovarian cancer
por: Liu, Ouxuan, et al.
Publicado: (2021)

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins
por: Gou, Rui, et al.
Publicado: (2019)

Prognostic biomarker MCP-4 triggers epithelial-mesenchymal transition via the p38 MAPK pathway in ovarian cancer
por: Li, Siting, et al.
Publicado: (2022)

Development of a seven-gene tumor immune microenvironment prognostic signature for high-risk grade III endometrial cancer
por: Zheng, Mingjun, et al.
Publicado: (2021)

HERPUD1 promotes ovarian cancer cell survival by sustaining autophagy and inhibit apoptosis via PI3K/AKT/mTOR and p38 MAPK signaling pathways
por: Nie, Xin, et al.
Publicado: (2022)

Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling
por: Wei, Yousheng, et al.
Publicado: (2020)

PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation
por: Li, Xiao, et al.
Publicado: (2023)

Identification of long noncoding RNA RP11-89K21.1 and RP11-357H14.17 as prognostic signature of endometrial carcinoma via integrated bioinformatics analysis
por: Gao, Lingling, et al.
Publicado: (2020)

Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway
por: Wang, Shuang, et al.
Publicado: (2020)

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
por: Zhou, Zhijun, et al.
Publicado: (2021)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
por: Przybytkowski, Ewa, et al.
Publicado: (2020)

Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments
por: Gao, Lingling, et al.
Publicado: (2020)

Interaction of CD147 and human epididymis protein 4 promotes invasion and metastasis of ovarian cancer
por: Gao, Lingling, et al.
Publicado: (2021)

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
por: Long, Junyu, et al.
Publicado: (2021)

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient
por: Han, Yuyi, et al.
Publicado: (2023)

Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma
por: Gao, Guangtao, et al.
Publicado: (2021)

Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
por: Kinget, Lisa, et al.
Publicado: (2021)

Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis
por: Zhou, Quanwei, et al.
Publicado: (2020)

Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling
por: Long, Shengrong, et al.
Publicado: (2020)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
por: Liu, Qian, et al.
Publicado: (2021)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Immune Checkpoint Blockers and Ovarian Cancer
por: Bose, Chinmoy K
Publicado: (2017)

Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy
por: Li, Zhe, et al.
Publicado: (2022)

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
por: Hua, Linbin, et al.
Publicado: (2023)

Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer
por: Wang, Xinjing, et al.
Publicado: (2021)

Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors
por: Jfri, Abdulhadi, et al.
Publicado: (2022)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
por: Hastings, K, et al.
Publicado: (2019)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value
por: Liu, Juan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ncuaulj2755lg2svn3jtprs0j